Phase II study of gemcitabine single agent for patients with advanced nasopharyngeal carcinoma (NPC) who failed to first line platinum-based chemotherapy

    2004.

    Cited by: 2|Bibtex|Views0|

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments